ClinicalTrials.gg
Not yet recruitingNCT07730580XNW5004 TabletUpdated Jul 28, 2026

Study of XNW5004 Tablets in Advanced Prostate Cancer

A Phase 2 interventional study of XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone and XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone in Advanced Prostate Cancer, sponsored by Evopoint Biosciences Inc.. Not yet recruiting. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Evopoint Biosciences Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing abiraterone in Prostatic Neoplasms — 17 open to participants now, 37 under way, 5 of them phase 3. abiraterone · Prostatic Neoplasms.

Planned enrollment
18th of 126
242 · median 51
Started
2026
with 1 other
Phase 2
79 of 126
13 open now
Primary completion
2028-12
later than 31 of 36 live
Registered
127th of 126
by date

Among the 126 studies testing abiraterone in Prostatic Neoplasms, this one is the 18th largest by planned enrollment, is one of 2 that started in 2026, is one of 79 in phase 2, reaches primary completion later than 31 of the 36 other live ones, and was the 127th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 126 studies testing abiraterone in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About abiraterone

abiraterone: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing abiraterone in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Phase Ib A preliminary design of 2 cohorts is planned for this phase, with 3-6 participants to be enrolled in each cohort. A total of 6-12 participants with advanced prostate cancer are planned to be enrolled in this phase. The study will be conducted at multiple investigational sites.

Phase II A preliminary design of 5 cohorts is planned for this phase. Cohorts 1, 2, and 3 are preset with 2 dose groups each, and each dose group plans to enroll 20-30 participants. Cohort 4 plans to enroll 20-50 participants. Cohort 5 will be adjusted based on results from prior study phases. A total of 140-230 participants with advanced prostate cancer are planned to be enrolled in this phase. The study will be conducted at multiple investigational sites.

Read the detailed description

This study consists of two phases. The first phase (Phase Ib) is a safety lead-in study of XNW5004 in combination with anti-tumor therapy; the second phase (Phase II) is a dose expansion study of XNW5004 in combination with anti-tumor therapy.

Phase Ib is a non-randomized, open-label study. Given the differences in mechanism of action, pharmacokinetic profiles, and toxicity profiles when XNW5004 is combined with different anti-tumor agents, the safety lead-in will be conducted independently for each combination cohort.

Upon completion of the Cycle 1 safety evaluation for the corresponding cohort in Phase Ib, the Phase II study will be initiated. Phase II is a randomized, open-label, dose expansion study. A preliminary design of 5 cohorts will further evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of XNW5004 in combination with anti-tumor therapy in participants with advanced prostate cancer.

The study process includes a screening period, a treatment period, and a follow-up period. Eligible participants after screening will enter the treatment period and receive therapy according to the combination regimen of their assigned cohort, until disease progression, death, withdrawal of informed consent, intolerable toxicity, or any other condition that the investigator deems necessary for study discontinuation.

Participants will undergo PK and PD blood sampling at designated time points, and relevant anti-tumor efficacy assessments will be performed.

03

Conditions studied

  • Advanced Prostate Cancer

Browse trials for

Keywords

  • XNW5004
  • Advanced Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

  1. Signed written prior to initiation of any study activity/procedure;
  2. Male, ≥18 years of age;
  3. Expected survival ≥ 3 months;
  4. performance status score of 0-1;
  5. or cytologically confirmed prostate adenocarcinoma of a single pathological type, excluding neuroendocrine carcinoma or small cell carcinoma;
  6. Bone lesions confirmed by bone scan, or soft tissue metastatic lesions confirmed by CT/MRI, with at least one evaluable lesion according to 1.1 and PCWG3 criteria. *Note:* Isolated regional lymph node metastasis alone does not qualify for study participation;
  7. Continuous luteinizing hormone-releasing hormone agonist (LHRHa) or antagonist therapy (medical castration), or prior bilateral orchiectomy (surgical castration); participants who have not undergone bilateral orchiectomy must plan to maintain effective LHRHa therapy throughout the entire study period;
  8. Castrate level of testosterone at screening (≤50 ng/dL or 1.7 nmol/L);
  9. Disease progression at screening, defined as meeting one or more of the following three criteria while receiving castration therapy: ① PSA progression, defined as PSA >1 ng/mL with at least 2 consecutive PSA elevations separated by ≥1 week; ② Disease progression per RECIST 1.1; ③ Bone disease progression per PCWG3 criteria, defined as ≥2 new lesions identified on bone scan;
  10. Prior antitumor therapy meets the following requirements:

    1. Phase Ib:

      • Cohort 1 (combination with abiraterone + prednisone for mCRPC):* Prior failure of novel hormonal therapy other than abiraterone acetate - defined as disease progression during treatment with novel hormonal therapy other than abiraterone (for at least 12 weeks) in the setting of mCSPC or mCRPC, or disease progression during treatment with novel hormonal therapy other than abiraterone (for at least 12 weeks) in the non-metastatic setting or within 3 months after completing such therapy; disease progression is defined as per Inclusion Criterion 9.
      • Cohort 2 (combination with docetaxel + prednisone for mCRPC):* Metastatic castration-resistant prostate cancer with prior failure of at least one novel hormonal therapy; failure of novel hormonal therapy is defined as per Cohort 1.
    2. Phase II:

      • Cohort 1 (combination with abiraterone + prednisone for mCRPC):* Prior failure of novel hormonal therapy other than abiraterone acetate - defined as disease progression during treatment with novel hormonal therapy other than abiraterone (for at least 12 weeks) in the setting of mCSPC or mCRPC, or disease progression during treatment with novel hormonal therapy other than abiraterone (for at least 12 weeks) in the non-metastatic setting or within 3 months after completing such therapy; disease progression is defined as per Inclusion Criterion 9.
      • Cohort 2 (combination with abiraterone + prednisone for mCSPC):No prior systemic antitumor therapy other than androgen deprivation therapy (ADT) and first-generation antiandrogens. Prior ADT (medical or surgical castration) for up to 3 months is allowed, with no evidence of radiographic disease progression or PSA elevation prior to Cycle 1 Day 1.
      • Cohort 3 (combination with docetaxel + prednisone for mCRPC):Metastatic castration-resistant prostate cancer with prior failure of at least one novel hormonal therapy; failure of novel hormonal therapy is defined as per Cohort 1.
      • Cohort 4 (combination with enzalutamide for mCSPC):No prior systemic antitumor therapy other than androgen deprivation therapy (ADT) and first-generation antiandrogens. Prior ADT (medical or surgical castration) for up to 3 months is allowed, with no evidence of radiographic disease progression or PSA elevation prior to Cycle 1 Day 1.
      • Cohort 5 (combination with other agents):Participants with advanced prostate cancer who have failed prior therapy other than the agent class of interest (to be specified via protocol amendment prior to cohort initiation).
  11. Participant laboratory values meet the following requirements:

    1. Hepatic function assessment:

      • (ALT) ≤ 2.5 × (≤ 5 × ULN for participants with liver metastases);
      • Aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN for participants with liver metastases);
      • Total ≤ 1.5 × ULN (≤ 3.0 × ULN for Gilbert's syndrome).
    2. Renal function assessment:**

      • ≥ 60 mL/min (per Cockcroft and Gault formula, Appendix 20.3), or serum creatinine ≤ 1.5 × ULN.
    3. Hematology assessment:**

      • (ANC) ≥ 1.0 × 10⁹/L (no granulocyte colony-stimulating factor [G-CSF] within 1 week, and no long-acting G-CSF within 2 weeks prior to screening CBC) - for non-docetaxel combination cohorts; Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L (no G-CSF within 1 week, and no long-acting G-CSF within 2 weeks prior to screening CBC) - for docetaxel combination cohorts;
      • ≥ 75 × 10⁹/L (no platelet transfusion and no thrombopoietin [TPO] within 1 week prior to screening CBC);
      • ≥ 8 g/dL (80 g/L) (no red blood cell transfusion and no erythropoietin [EPO] within 1 week prior to screening CBC).
    4. Coagulation assessment:

      • (PT) \< 1.5 × ULN, or international normalized ratio (INR) \< 1.5 × ULN; if the participant is currently on anticoagulant therapy, INR ≤ 3 × ULN.
  12. Must agree to use adequate from study initiation through at least 6 months after the last dose of study drug, and must refrain from sperm donation;
  13. Able to comply with all study procedures as judged by the investigator.

Exclusion Criteria:

Participants meeting any of the following criteria will not be eligible for enrollment in this study:

  1. Prior antitumor therapy meets the following conditions:

    1. Phase Ib:

      • Cohort 1: Prior treatment with abiraterone or cytotoxic chemotherapy (including but not limited to antibody-drug conjugates [ADCs] with cytotoxic payload). *Note:* Docetaxel use during the hormone-sensitive setting is allowed, provided there was no treatment failure or disease progression during therapy or within 3 months after completion.
      • Cohort 2: Prior cytotoxic chemotherapy (including but not limited to ADCs with cytotoxic payload) at any stage of prostate cancer. *Note:* Docetaxel use during the hormone-sensitive setting is allowed, provided there was no treatment failure or disease progression during therapy or within 3 months after completion.
    2. Phase II:

      • Cohort 1: Prior treatment with abiraterone or cytotoxic chemotherapy (including but not limited to ADCs with cytotoxic payload). *Note:* Docetaxel use during the hormone-sensitive setting is allowed, provided there was no treatment failure or disease progression during therapy or within 3 months after completion.
      • Cohort 2:Participants must be treatment-naïve in the metastatic castration-sensitive prostate cancer (mCSPC) setting; i.e., participants must not have received any cytotoxic chemotherapy (including but not limited to ADCs with cytotoxic payload), with the exception that first-generation antiandrogen (ADT) therapy is allowed during the mCSPC stage.
      • Cohort 3:Participants must not have received any cytotoxic chemotherapy (including but not limited to ADCs with cytotoxic payload). *Note:* Docetaxel use during the hormone-sensitive setting is allowed, provided there was no treatment failure or disease progression during therapy or within 3 months after completion.
      • Cohort 4: Participants must be treatment-naïve in the metastatic castration-sensitive prostate cancer (mCSPC) setting; i.e., participants must not have received any cytotoxic chemotherapy (including but not limited to ADCs with cytotoxic payload), with the exception that first-generation antiandrogen (ADT) therapy is allowed during the mCSPC stage.
  2. Prior treatment with agents similar to or targeting the same pathway as the study drug (including but not limited to tazemetostat, EZH1/2 inhibitors, and EED inhibitors);
  3. Received chemotherapy, immunotherapy, definitive radiotherapy, targeted therapy, anti-tumor traditional Chinese medicine, or other anti-tumor therapies within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose; palliative radiotherapy within 2 weeks prior to the first dose;
  4. Planned receipt of any other anti-tumor therapy during the study period;
  5. Received any other product not yet approved in the study region within 28 days prior to the first dose of this study (i.e., last dose of investigational product within 28 days of the first study drug dose);
  6. Presence of central nervous system (CNS) metastases; history of or concurrent CNS conditions including but not limited to epilepsy, paralysis, stroke, severe brain injury, Alzheimer's disease, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, spinal cord compression, or cauda equina syndrome (with the exception of stroke that was adequately treated and stable for ≥12 months prior to first dose, or asymptomatic/untreated lacunar infarction);
  7. Severe bone damage due to tumor bone metastases as judged by the investigator, including poorly controlled severe bone pain, pathological fractures at critical sites occurring within the last 6 months or expected in the near future, and spinal cord compression;
  8. History of other within 3 years prior to enrollment that does not meet clinical cure criteria. Exceptions: basal cell carcinoma or squamous cell carcinoma of the skin that has been locally treated and cured, superficial bladder cancer, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma;
  9. Poorly controlled bladder outlet obstruction or urinary incontinence as judged by the investigator;
  10. Impaired cardiac function or cardiac disease, including any of the following:

    1. Acute myocardial infarction or unstable angina ≤ 6 months prior to first dose;
    2. Congestive heart failure ( [NYHA] Class III or IV), (LVEF) \< 50%;
    3. Uncorrected serious arrhythmia, hypertension ≥ 150/100 mmHg;
    4. Prolonged (defined as >450 ms for males, >470 ms for females) per Fridericia's formula (see Appendix 20.4);
    5. History of other major cardiovascular disease (e.g., valve replacement, coronary artery bypass grafting, etc.);
  11. Active systemic severe infection: a of at least 2 weeks is required after completion of antifungal therapy (whether intravenous or oral); at least 1 week washout after completion of other intravenous anti-infective therapy; other oral anti-infective therapy must meet discontinuation criteria and be stopped prior to the first study dose;
  12. History of tuberculosis infection within 1 year prior to enrollment, or history of active tuberculosis infection more than 1 year ago without adequate anti-tuberculosis treatment;
  13. Known to the study drug or its active ingredients or ;
  14. Use of known moderate or strong inducers or inhibitors within 14 days prior to the first dose (see Appendix 20.5);
  15. Active and inflammatory diseases, such as systemic lupus erythematosus, psoriasis requiring systemic therapy, rheumatoid arthritis, inflammatory bowel disease, and Hashimoto's thyroiditis; with the exception of Type 1 diabetes mellitus, hypothyroidism controlled solely by replacement therapy, hyperthyroidism stable on medication, and skin conditions not requiring systemic therapy (e.g., vitiligo, localized psoriasis);
  16. History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring therapy, or any evidence of clinically active ILD;
  17. Known gastrointestinal (GI) function impairment or GI conditions that may significantly affect the absorption or metabolism of oral medications; abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to the first dose;
  18. (HIV) positive, or syphilis (Anti-TP) positive (not excluded if non-treponemal syphilis test is negative and the investigator determines syphilis has been cured);
  19. Known acute or chronic active (HBsAg positive or HBcAb positive with HBV DNA ≥ 200 IU/mL or ≥ 10³ copies/mL), or acute or chronic active (HCV antibody positive with HCV RNA positive);
  20. Toxicities from prior anti-tumor therapy that have not resolved (not recovered to ≤ Grade 1 per Version 6.0). Exceptions include other toxicities that the investigator deems do not affect participant safety assessment (e.g., alopecia);
  21. Symptomatic pleural effusion, ascites, or pericardial effusion that is poorly controlled despite repeated treatment;
  22. Prior allogeneic tissue or solid organ transplantation;
  23. Major surgery within 4 weeks prior to dosing, or planned major surgery during the study period (excluding procedures such as puncture or lymph node );
  24. Received (including live attenuated vaccine) within 28 days prior to dosing; inactivated vaccines are allowed;
  25. Baseline bone scan showing a "superscan" pattern that precludes assessment of new bone metastases;
  26. Any other condition that, in the investigator's judgment, makes the participant unsuitable for enrollment.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
242 participants (estimated)

Study arms

  • Experimental
    mCRPC (Prior NHT Failure Excluding Abiraterone) - XNW5004 + Abiraterone + Prednisone

    Participants with metastatic castration-resistant prostate cancer (mCRPC) who have previously failed novel hormonal therapy other than abiraterone acetate will be enrolled.

    Drug: XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone

  • Experimental
    mCRPC with Prior NHT Failure - XNW5004 + Docetaxel + Prednisone

    Participants with mCRPC who have failed at least one prior line of novel hormonal therapy will be enrolled.

    Drug: XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone

  • Active comparator
    Randomized mCRPC (Prior NHT Failure Excluding Abiraterone) - XNW5004 + Abiraterone + Prednisone

    Participants with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior novel hormonal therapy other than abiraterone acetate will be enrolled.

    Drug: XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID

  • Active comparator
    mCSPC

    Participants with mCRPC who have failed at least one prior line of novel hormonal therapy are eligible for enrollment.

    Drug: XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO, QDD

  • Active comparator
    Randomized mCRPC (Prior NHT Failure) - XNW5004 + Docetaxel + Prednisone

    Participants with mCRPC who have failed at least one prior line of novel hormonal therapy will be enrolled.

    Drug: XNW5004 800/1200 mg BID in Combination with Docetaxel plus Prednisone

  • Experimental
    mCSPC Treated with XNW5004 in Combination with Enzalutamide

    Participants with mCSPC will be enrolled and will receive XNW5004 in combination with enzalutamide.

    Drug: XNW5004 1200 mg, PO, BID (10-14 hours interval between two doses, taken with warm water); Enzalutamide 160 mg, PO, QD. Each treatment cycle consists of 4 weeks.

  • Experimental
    XNW5004 + Anti-Tumor Therapy

    Participants with advanced prostate cancer will be enrolled and will receive XNW5004 in combination with other anti-tumor therapies. The subsequent development plan for this cohort will be determined based on results from prior study phases.

    Drug: Subsequent development plans will be determined based on preliminary study results.

Interventions

  • DrugXNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone

    Drug pages: XNW5004 · Abiraterone · Prednisone

    Ib Cohort 1: XNW5004 1200 mg, PO, BID (10-14 hours interval between two doses, taken with warm water); Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; Prednisone 5 mg PO, BID (prednisone dosing frequency may be adjusted at the investigator's discretion).

  • DrugXNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone

    Drug pages: XNW5004 · Docetaxel · Prednisone

    Ib Cohort 2: XNW5004 1200 mg, PO, BID (10-14 hours interval between two doses, taken with warm water), administered continuously until disease progression, death, withdrawal of informed consent, intolerable toxicity, or any other condition that the investigator deems necessary for study discontinuation. Docetaxel 75 mg/m², intravenous (IV), Day 1; Prednisone tablets 5 mg, PO, BID, taken continuously.

  • DrugXNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID

    XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO, BID or QD. Required first-dose sequence on Day 1 and Day 28 of Cycle 1 for the first 10 participants in each dose cohort: Take abiraterone first; consume a meal 1 hour after abiraterone administration; take XNW5004 tablets plus prednisone simultaneously 1.5 hours after abiraterone administration.

  • DrugXNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO, QDD

    XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO, QD. Required first-dose sequence on Day 1 and Day 28 of Cycle 1 for the first 10 participants in each dose cohort: Take abiraterone first; consume a meal 1 hour after abiraterone administration; take XNW5004 tablets plus prednisone simultaneously 1.5 hours after abiraterone administration.

  • DrugXNW5004 800/1200 mg BID in Combination with Docetaxel plus Prednisone

    XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID, administered continuously until disease progression, death, withdrawal of informed consent, intolerable toxicity, or any other condition that the investigator deems necessary for study discontinuation. Docetaxel 75 mg/m², intravenous (IV), Day 1 (premedication prior to docetaxel administration shall follow the prescribing information and standard clinical practice of the study center); plus Prednisone tablets 5 mg, PO, BID, taken continuously.

  • DrugXNW5004 1200 mg, PO, BID (10-14 hours interval between two doses, taken with warm water); Enzalutamide 160 mg, PO, QD. Each treatment cycle consists of 4 weeks.

    Drug page: XNW5004

    XNW5004 1200 mg, PO, BID (10-14 hours interval between two doses, taken with warm water); Enzalutamide 160 mg, PO, QD. Each treatment cycle consists of 4 weeks.

  • DrugSubsequent development plans will be determined based on preliminary study results.

    Subsequent development plans will be determined based on preliminary study results.

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-Free Survival

    Time frame: 24months

  2. Recommended Phase 3 Dose(Phase II Cohorts 1, 2, and 3)

    Time frame: 24 months

Secondary outcomes

  1. Time to PSA Progression

    Time frame: 24 months

  2. PSA Response Rate at Week 12

    Time frame: 24 months

  3. Proportion of Participants with PSA Reduction ≥50% from Baseline During Entire Treatment Period

    Time frame: 24 months

  4. Time to First Symptomatic Skeletal Event

    Time frame: 24 months

  5. Objective Response Rate (ORR) per RECIST 1.1 and PCWG3

    Time frame: 24 months

  6. Disease Control Rate (DCR) per RECIST 1.1 and PCWG3

    Time frame: 24 months

  7. Duration of Response (DOR) per RECIST 1.1 and PCWG3

    Time frame: 24 months

  8. Overall Survival (OS) per RECIST 1.1 and PCWG3

    Time frame: 24 months

  9. Safety Endpoints:Incidence of Adverse Events

    Time frame: 24 months

  10. Safety Endpoints:Severity of Adverse Events

    Time frame: 24 months

  11. Safety Endpoints:Abnormal Laboratory Parameters

    Time frame: 24 months

  12. Area under the plasma concentration-time curve (AUC)

    Time frame: 24 months

  13. Maximum (Peak) Plasma Concentration (Cmax)

    Time frame: months

  14. Maximum (Peak) Plasma Concentration at Steady State (Css,max)

    Time frame: 24 months

  15. Area under the plasma concentration-time curve at Steady State (AUCss)

    Time frame: 24 months

  16. Time to Peak Concentration (Tmax)

    Time frame: 24 months

  17. Elimination Half-Life (t₁/₂)

    Time frame: 24 months

  18. Mean Residence Time (MRT)

    Time frame: 24 months

  19. Apparent Volume of Distribution at Terminal Phase (Vz/F)

    Time frame: 24 months

  20. Apparent Clearance (CL/F)

    Time frame: 24 months

  21. Accumulation Ratio (Rac)

    Time frame: 24 months

  22. Change from Baseline in H3K27me3 / Histone H3 Ratio

    Time frame: 24 months

Other outcomes

  1. Retrospective Analysis of Correlation Between Biomarkers (Including AR-V7) and Efficacy

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2028, 29 months later.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 29 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 28, 2026
StartEst.
Jul 13, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07730580
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Jul 13, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 28, 2026

Study contacts

Junjie Zhang Central Contact Person
Contact
junjie.zhang@evopointbio.com
86+15010250838

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: XNW5004 · Abiraterone · Prednisone · Docetaxel

Start the discussion